ClinicalTrials.gg
CompletedNCT01831960Updated Dec 2, 2020Results posted

An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris

A Phase 2 interventional study of cortexolone 17α-propionate in Acne Vulgaris, sponsored by Intrepid Therapeutics, Inc.. Completed at 3 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-12-02.

Sponsored by Intrepid Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing clascoterone in Acne Vulgaris — 5 open to participants now, 7 under way, 2 of them phase 3. Clascoterone · Acne Vulgaris.

Enrollment
11th of 19
42 · median 50
Started
2013
the only one that year
Phase 2
3 of 19
none open now
Registered
2nd of 19
by date
Lead sponsor
2 of 19
Intrepid Therapeutics, Inc.

Among the 19 studies testing clascoterone in Acne Vulgaris, this one is the 11th largest by enrollment, is the only one that started in 2013, is one of 3 in phase 2, and was the 2nd registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

5 of the 19 studies testing clascoterone in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About clascoterone

Clascoterone: first FDA approval 2020 (WINLEVI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing clascoterone in Acne Vulgaris, or all of them as a file.
02

Study summary

This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve hours for two weeks, in subjects with acne vulgaris ages 12 years or older.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • Cassiopea
  • clascoterone
  • cortexolone 17α-propionate
  • anti-androgen
  • CB-01-03
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has moderate to severe facial acne vulgaris as determined by the Investigator's Global Assessment (IGA) and obvious acne on the chest and/or back at study start.
  • Subject has facial acne vulgaris (including the nose) with a minimum number of inflammatory lesions (papules, pustules, and nodules/cysts) and a minimum number of non-inflammatory lesions (open and closed comedones) at study start.
  • Females must be , surgically sterile or using highly effective methods with a negative urine pregnancy test (UPT) at study start.
  • Subject must be in general good health in the opinion of the investigator, with normal renal function, based on screening physical examination, medical history, and clinical laboratory values.

Exclusion criteria

Exclusion Criteria:

  • Subject is pregnant, lactating, or is planning to become pregnant during the study.
  • Subject is 12-20 years of age and has a (BMI) for age percentile > 85%.
  • Subject is > 20 years of age and has a BMI > 32.0 kg/m2.
  • Subject has used tobacco, smoking cessation products, or products containing nicotine within three months prior to study start.
  • Except for the use of , subject has used any prescription drug or herbal product within 14 days prior to dosing, any non-prescription drug or vitamin or mineral supplements within 7 days prior to study start; any known enzyme-inducer, enzyme-inhibitor, or reported chronic exposure to enzyme-inducers such as paint solvents or pesticides within 30 days of study start.
  • Subject has used topical anti-acne medications containing retinoids such as tazarotene, adapalene or tretinoin, within four weeks of study start.
  • Subject has used the following systemic anti-acne medications: antibiotics within two weeks of study start, spironolactone within four weeks of study start, or retinoid therapy within three months of study start.
  • Subject has any skin or medical condition, including facial hair that could interfere with the evaluation of the test article or requires the use of interfering topical or systemic therapy.
  • Subject has the need or plans to be exposed to artificial tanning devices or excessive sunlight during the study.
  • Subject has used light treatments, microdermabrasion or chemical peels to the face, chest and back within eight weeks of study start.
  • Subject cannot avoid any type of strenuous exercise (swimming, running, team sports, etc.,) or the use of hot tubs/saunas from study start to the end of the study.
  • Subject has received an drug or been treated with an investigational device within 30 days prior to study start.
  • Subject is currently enrolled in an investigational drug or device study.
  • Subject has used topical (including inhaled and intranasal corticosteroids) within two weeks of study start.
  • Subject has used systemic corticosteroids (including intramuscular and intralesional injections) within four weeks of study start.
  • Subject has an irregular sleep schedule or works night shifts.
  • Subject has experienced significant blood loss within 60 days or has donated plasma within 72 hours prior to study start.
  • Subject tests positive at Screening for (HIV) or is known to be seropositive for HIV.
  • Subject tests positive at Screening for surface antigen, antibody or has a history of a positive result.
  • Subject had major surgery within 30 days prior to study start or plans to have surgery during the study.
  • Subject has participated in a previous CB-03-01 study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Cortexolone 17α-Propionate

    Topical cream, 1.0% concentration, applied every twelve hours

    Drug: cortexolone 17α-propionate

Interventions

06

What researchers measure

Primary outcomes

  1. Change in HPA Axis Response to Cosyntropin

    Measurement of serum cortisol concentrations after stimulation of the adrenal cortex with cosyntropin injection (Cosyntropin Stimulation Test - CST). Prior to CST, a pre-CST blood sample is taken between 7AM to 9AM. Thirty minutes after CST, a post-CST blood sample is collected. HPA axis suppression is defined as a post-stimulation serum cortisol level ≤ 18 μg/dL at Day 14.

    Time frame: Baseline and Day 14

  2. PK Profiles (Cmax) of Cortexolone 17α-propionate

    Max concentration (Cmax) of cortexolone 17α-propionate in plasma following the first application (i.e., Day 1, 0-12 hours) and last application (i.e., Day 14, 0-12 hours).

    Time frame: Baseline and Day 14

  3. PK Profiles (AUC) of Cortexolone 17α-propionate

    Area under the plasma concentration curve (0-12 hours) of cortexolone 17α-propionate at baseline (i.e., Day 1, after first application \[0-12 hours\]) and at Day 14 (i.e., Day 14, after last application \[0-12 hours\]).

    Time frame: Baseline and Day 14

  4. PK Profiles (Cavg) of Cortexolone 17α-propionate

    Average concentration of cortexolone 17α-propionate in plasma calculated as the ratio of the AUC(0-12 hours) and the dosing interval (i.e., 12 hours) at baseline (i.e., Day 1, after first application) and at Day 14 (after last application).

    Time frame: Baseline and Day 14

07

Results

Posted Nov 17, 2020

Participant flow

Participant flow — Overall Study
MilestoneCortexolone 17α-Propionate (Cohort 1)Cortexolone 17α-Propionate (Cohort 2)
Started2022
Completed2022
Not completed00

Outcome measures

PrimaryChange in HPA Axis Response to Cosyntropin

Measurement of serum cortisol concentrations after stimulation of the adrenal cortex with cosyntropin injection (Cosyntropin Stimulation Test - CST). Prior to CST, a pre-CST blood sample is taken between 7AM to 9AM. Thirty minutes after CST, a post-CST blood sample is collected. HPA axis suppression is defined as a post-stimulation serum cortisol level ≤ 18 μg/dL at Day 14.

Time frame:
Baseline and Day 14
Reported as:
Mean · mcg/dL
Change in HPA Axis Response to Cosyntropin
mcg/dLCortexolone 17α-Propionate (Cohort 1)Cortexolone 17α-Propionate (Cohort 2)
Baseline (pre-CST)17.0 ± 5.9816.8 ± 4.71
Baseline (post-CST)27.7 ± 3.4324.6 ± 3.12
Day 14 (pre-CST)18.1 ± 7.0215.4 ± 3.98
Day 14 (post-CST)26.7 ± 5.5622.8 ± 2.99
PrimaryPK Profiles (Cmax) of Cortexolone 17α-propionate

Max concentration (Cmax) of cortexolone 17α-propionate in plasma following the first application (i.e., Day 1, 0-12 hours) and last application (i.e., Day 14, 0-12 hours).

Time frame:
Baseline and Day 14
Reported as:
Mean · ng/mL
PK Profiles (Cmax) of Cortexolone 17α-propionate
ng/mLCortexolone 17α-Propionate (Cohort 1)Cortexolone 17α-Propionate (Cohort 2)
Cmax - Day 1 (ng/mL)3.23 ± 2.013.58 ± 4.30
Cmax - Day 14 (ng/mL)4.46 ± 3.004.61 ± 4.74
PrimaryPK Profiles (AUC) of Cortexolone 17α-propionate

Area under the plasma concentration curve (0-12 hours) of cortexolone 17α-propionate at baseline (i.e., Day 1, after first application \[0-12 hours\]) and at Day 14 (i.e., Day 14, after last application \[0-12 hours\]).

Time frame:
Baseline and Day 14
Reported as:
Mean · hr*ng/mL
PK Profiles (AUC) of Cortexolone 17α-propionate
hr*ng/mLCortexolone 17α-Propionate (Cohort 1)Cortexolone 17α-Propionate (Cohort 2)
AUCτ - Day 122.02 ± 13.6722.55 ± 22.57
AUCτ - Day 1437.14 ± 22.9230.97 ± 24.65
PrimaryPK Profiles (Cavg) of Cortexolone 17α-propionate

Average concentration of cortexolone 17α-propionate in plasma calculated as the ratio of the AUC(0-12 hours) and the dosing interval (i.e., 12 hours) at baseline (i.e., Day 1, after first application) and at Day 14 (after last application).

Time frame:
Baseline and Day 14
Reported as:
Mean · ng/mL
PK Profiles (Cavg) of Cortexolone 17α-propionate
ng/mLCortexolone 17α-Propionate (Cohort 1)Cortexolone 17α-Propionate (Cohort 2)
Cavg - Day 11.84 ± 1.141.88 ± 1.88
Cavg - Day 143.10 ± 1.912.58 ± 2.05

Adverse events

Collected over 14 Days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cortexolone 17α-Propionate (Cohort 1)0/20 (0%)0/20 (0%)5/20 (25%)
Cortexolone 17α-Propionate (Cohort 2)0/22 (0%)0/22 (0%)3/22 (13.6%)
Most frequent other events
Most frequent other events
EventCortexolone 17α-Propionate (Cohort 1)Cortexolone 17α-Propionate (Cohort 2)
ACTH stimulation test abnormalInvestigations1/202/22
DiarrhoeaGastrointestinal disorders1/200/22
Application site folliculitisGeneral disorders1/200/22
Upper respiratory tract infectionInfections and infestations1/201/22
EcchymosisSkin and subcutaneous tissue disorders1/200/22
Ear infectionInfections and infestations0/201/22

Baseline characteristics

Forty-two (42) subjects were enrolled into the study across two cohorts dependent upon age: Cohort 1: 20 adult subjects Cohort 2: 22 adolescent (12 to less than 18 years of age) subjects

Age, Continuous
Age, Continuous(years)Cortexolone 17α-Propionate (Cohort 1)Cortexolone 17α-Propionate (Cohort 2)Total
Mean24.4 ± 5.8415.6 ± 1.3319.8 ± 6.02
Sex: Female, Male
Sex: Female, Male(Participants)Cortexolone 17α-Propionate (Cohort 1)Cortexolone 17α-Propionate (Cohort 2)Total
Female151227
Male51015
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cortexolone 17α-Propionate (Cohort 1)Cortexolone 17α-Propionate (Cohort 2)Total
Hispanic or Latino011
Not Hispanic or Latino202141
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cortexolone 17α-Propionate (Cohort 1)Cortexolone 17α-Propionate (Cohort 2)Total
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American101
White172138
More than one race112
Unknown or Not Reported000
08

Study locations

3 sites
  • Northwest Clinical Trials, Inc.
    Boise, Idaho, United States
  • Shideler Clinical Research Center
    Carmel, Indiana, United States
  • Michigan Center for Research Corp.
    Clinton Township, Michigan, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2020, 7 years after primary completion. A results delay was requested in Mar 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2013
First posted
Apr 15, 2013
Start
Apr 2013
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Results delay requested
Mar 27, 2015
Results first posted
Nov 17, 2020
Last update
Dec 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01831960
Lead sponsor
Intrepid Therapeutics, Inc.
Responsible party
Sponsor
First posted
Apr 15, 2013
Start date
Apr 2013
Primary completion
Nov 2013
Completion
Nov 2013
Results posted
Nov 17, 2020
Last update
Dec 2, 2020

Study contacts

R&D Cassiopea
study director · Cassiopea S.p.A.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clascoterone

Start the discussion